Figure 1. Flowchart of the study. A total of 903 HCC patients from five separate datasets were included in the analysis. We developed the immune-based prognostic signature for HCC (IPSHCC) using the training dataset and validated it in five independent validation subsets. We also integrated IPSHCC with stage, invasion, age, and gender to improve its prognostic value.